ESR1 and neoplasm: Together, our data demonstrate a novel tumor-promoting function for the Notch ligand, DLL1 in ERα+ luminal breast cancers, thereby providing initial proof-of-principle for subtype-specific therapies for luminal ERα+ breast cancer patients.